Powered by OpenAIRE graph
Found an issue? Give us feedback

UPC

Universitat Politècnica de Catalunya
Country: Spain
Funder
Top 100 values are shown in the filters
Results number
arrow_drop_down
511 Projects, page 1 of 103
  • Funder: EC Project Code: 294229
    visibility244
    visibilityviews244
    downloaddownloads767
    Powered by Usage counts
    more_vert
  • Funder: EC Project Code: 101055053
    Overall Budget: 2,497,330 EURFunder Contribution: 2,497,330 EUR

    Bacterial bone infections are one of the great challenges of orthopaedic and maxillofacial surgery, aggravated by antibiotic resistance, a serious health threat responsible for 700,000 deaths per year. The recent discovery of the bactericidal properties of some naturally occurring surface topographies has opened a new avenue of research. However, there is incomplete knowledge of the mechanisms of action and too many unanswered questions to translate these advances into clinical use. BAMBBI aims to tackle this challenge by developing synthetic bone grafts featuring contact-based antimicrobial properties, adding antimicrobial activity to their capacity to support bone regeneration. Using a novel bottom-up approach inspired in biomineralization routes, I intend to engineer the surface of calcium phosphates with an unprecedented and fine control of nanotopography by harnessing the power of ions and organic molecules (e.g. amino acids, calcium chelators and surfactants) to drive crystal nucleation and growth. Moreover, we will further enhance the antimicrobial effect by exploiting the synergy with chemical moieties to modulate bacterial affinity for the surface and/or confer additional antimicrobial properties by immobilisation of antimicrobial peptides. This will provide us with a platform to study the contact-based bactericidal mechanisms in depth and unravel the role of nanotopography and surface chemistry and their interplay with the intrinsic properties of bacteria. Only considering all these parameters will it be possible to unveil the causes of the substantial differences in bactericidal efficacy of a given substrate for different bacteria and design more efficient antibacterial surfaces. In addition to being a major breakthrough in the field of bone regeneration, the progress in new methods of fine-tuning the nanostructure of calcium phosphates will have an impact in very diverse fields such as catalysis, water purification and protein separation.

    more_vert
  • Funder: EC Project Code: 632458
    visibility111
    visibilityviews111
    downloaddownloads690
    Powered by Usage counts
    more_vert
  • Funder: EC Project Code: 101082096
    Funder Contribution: 150,000 EUR

    Improving the survival of patients with osteosarcoma has long proved challenging. Osteosarcoma is a rare bone cancer (less than 0.2% of all cancers). However, it affects mainly children and young adolescents. The standard therapy for osteosarcoma consists in the surgeon removing the entire tumor with negative margins (resection of larger areas of bone than the tumor itself), to ensure that no cancer cells are found at the edge of the tissue removed. This means that in some cases these surgeries associate limb amputation and even when it is not the case, most patients that undergo limb-sparing surgery need reconstructive surgery to regain limb function. The aim of TRANSFORMER is to bring closer to the market a solution that will allow to simultaneously treat bone cancer in absence of side effects while allowing bone regeneration. The product to be developed in TRANSFORMER puts together for the first time bone regeneration biomaterials with an innovative therapy for cancer that – in contrast to chemotherapy – up to now has shown no secondary effects: cold atmospheric plasma-treated hydrogels. The technology is protected by two PCT. TRANSFORMER value proposition: the product focused in in TRANSFORMER will have a double advantage for the patients and clinicians: it will be a local therapy that will allow simultaneous bone cancer treatment and bone regeneration. TRANSFORMER is structured along several objectives: (i) to preclinically validate the plasma-treated biocomposite as a potential therapy against bone cancer and towards bone regeneration, advancing the technology from TRL of 3 to 5, subsequently making it ready for clinical development and transfer to a spin-off or a third party company. (ii) To consolidate our IP position. (iii) To adapt the development roadmap to the regulatory requirements. (iv) To build a comprehensive business case for the exploitation of the technology and subsequent strategy for knowledge transfer.

    more_vert
  • Funder: EC Project Code: 620087
    more_vert
Powered by OpenAIRE graph
Found an issue? Give us feedback

Do the share buttons not appear? Please make sure, any blocking addon is disabled, and then reload the page.

Content report
No reports available
Funder report
No option selected
arrow_drop_down

Do you wish to download a CSV file? Note that this process may take a while.

There was an error in csv downloading. Please try again later.